

FINANCIAL TEAR SHEET

Corporate Profile

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

Primary IR Contact


E-mail: irdept@flex-pharma.com

Stock Performance

FLKS (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$3.60
Change (%)	▲ 0.10 (2.86%)
Volume	25,623
52 Week Low	\$3.01
Market Cap	\$62,901,356
Rolling EPS	-2.13
PE Ratio	0
Shares Outstanding	17,971,816

Data as of 08/17/17 4:00 p.m. ET



Symbol
FLKS (Common Stock)

Time Frame

Frequency

Chart Type

Recent Headlines & Events

08/02/17 - 7:30 a.m.

[Flex Pharma Reports Second Quarter 2017 Financial Results](#)

08/01/17 - 7:30 a.m.

[Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US](#)

07/31/17 - 7:30 a.m.

[Flex Pharma Names William McVicar President and Chief Executive Officer](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/02/17	10-Q
08/02/17	8-K
07/27/17	4
07/27/17	4

Fundamentals, Copyright Thomson Reuters Corporation

Data Provided by Thomson Reuters

Minimum 20 minutes delayed